Mahaweni, Niken M.
Bos, Gerard M. J.
Mitsiades, Constantine S.
Tilanus, Marcel G. J.
Wieten, Lotte
Funding for this research was provided by:
KWF Kankerbestrijding (UM2012 - 5375)
Kankeronderzoeksfonds Limburg
Article History
Received: 8 May 2017
Accepted: 22 February 2018
First Online: 2 March 2018
Compliance with ethical standards
:
: G. M. J. Bos is Chief Executive Officer/Chief Medical Officer/Co-founder of CiMaas, BV, Maastricht, The Netherlands. CiMaas is producing an ex vivo expanded NK cell product that will be used to treat myeloma patients. The other authors declare no conflict of interest.